Guest Post: From lab to jab: Vaccine development to prevent COVID-19
By Guest Contributor | June 11, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
What scientific experts are saying about vaccine safety
By Andrew Powaleny | June 4, 2020
Vaccines have played a critical role in reducing the spread of, and in some cases, eliminating the threat of many devastating infectious diseases. They are often cited as second only to clean...
Read More
Guest Post: What will we learn from COVID-19?
By Guest Contributor | May 27, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
By Richard Moscicki, M.D. | May 18, 2020
This week is Clinical Trials Awareness Week — an event to recognize the importance of clinical trials, raise public awareness of clinical research and honor clinical research professionals and...
Read More
Guest Post: Preserving clinical research sites during the coronavirus pandemic
By Guest Contributor | April 29, 2020
Conversations and healthy debate about issues facing our industry and the healthcare system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New report shows nearly 260 vaccines in development, including dozens for COVID-19
By Andrew Powaleny | April 23, 2020
Vaccines represent some of the most impactful advances in public health, helping to prevent the spread of many infectious diseases and, in many parts of the world, eliminating some of the most...
Read More
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
By Andrew Powaleny | April 6, 2020
As America’s biopharmaceutical companies work around the clock to combat COVID-19, a disease caused by a novel strain of coronavirus, now is an important time to consider how we can prepare for...
Read More
The biopharmaceutical industry’s unique role in responding to COVID-19
By Richard Moscicki, M.D. | April 2, 2020
As the outbreak of COVID-19, a disease caused by a novel strain of coronavirus, evolves in the United States and around the globe, both the private and public sectors are working around the clock...
Read More
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
By Gabby Migliara | April 1, 2020
Recently, PhRMA hosted a teleconference to provide an update on our member companies’ around-the-clock efforts in developing treatments and vaccines for COVID-19, a disease caused by a novel...
Read More
COVID-19 Response: Supporting the frontline
By Stephen J. Ubl | March 30, 2020
Updated 7/13/2020 In these unprecedented times, America’s biopharmaceutical companies are coming together to achieve one shared goal: to combat COVID-19, a disease caused by a novel strain of...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
